The following is a summary of “Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis” published in the December 2022 issue of Clinical Lung Cancer by Maller et al.

A major issue with lung cancer is metastasis to the intraocular structures. However, scant data is available on treatment outcomes and prognosis because of its rarity. The prognosis is usually bleak in the literature. Here, researchers take a look at the latest research on the effects of systemic treatment and associated prognostic variables. By searching databases like Medline and Google Scholar, they were able to compile a comprehensive list of relevant English-language articles published between 2009 and 2022. Patients with intraocular metastases from lung cancer were included if there was a report of tumor response in the eyes or overall survival in the literature. They used patient-level data to conduct a pooled analysis of those receiving systemic treatment.

There were a total of 92 patients included in the research based on data from 79 publications. In 82% of cases, the choroid was the damaged intraocular structure. Only 13% of the samples had small cell histology, while 87% did not. About 45% received some sort of targeted therapy. The average overall survival time was 27 months (95% CI, 21.8-32.2) in a large study that included data from multiple institutions. About 92% of individuals who reported an assessment of their eyesight said their vision was stable or improved, while 8% said it had worsened. Age at diagnosis, kind of treatment, the effectiveness of targeted therapy, and effectiveness of radiation all played a role in determining whether or not a patient lived. Receiving targeted therapy was the most important factor in predicting increased survival, with a hazard ratio of 0.31 (95% CI, 0.14-0.71, P=.005).

Systemic therapy is associated with a positive outcome for individuals with lung cancer who have developed intraocular metastases. Long-term survival is possible, especially when focused therapy can be administered.